Functional secondary outcome parameters in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving prostatic artery.

Slides:



Advertisements
Similar presentations
OnabotulinumtoxinA for Urinary Incontinence from Neurogenic Detrusor Overactivity.
Advertisements

MODULE 5 1/23 Case 9: Pierre. MODULE 5 Case 9: Pierre 2/23 Patient History  Pierre is 65 years of age who has suffered with benign prostatic hyperplasia.
Benign Prostatic Hyperplasia Dr.Bandar Al Hubaishy Urology Department KAUH.
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
Benign Prostatic Hyperplasia
Urology Update Sanofi- Aventis
Check your knowledge in… BHP/LUTS. 5-alpha-reductase inhibitors in the treatment of BPH Induce a significant decrease of libido 2 - Increase maximum.
Figure 1. Gross specimen of prostate gland.. Figure 2. Microscopic effects of BPH.
MEDICAL CORRECTION OF DISORDERS OF URINATION AFTER THE TRANSURETHRAL RESECTION OF BENIGN PROSTATIC HYPERPLASIA. О.О. Stroy, А.V. Shulyak, Borys B. Yu.,
The GOLIATH Study ..
Genitourinary Blueprint
Department of Urology, Guangzhou First Municipal People’s Hospital, Guangzhou Medical College, Guangzhou, China Rubiao Ou, Meng You, Ping Tang, Hui Chen,
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Increasing Doses of Saw Palmetto Extract.
Prostate artery embolization (PAE) for bladder outflow obstruction: Results from the first UK prospective study Dyer J P, Bryant T, Coyne J, Flowers D,
Noninvasive Urodynamic Evaluation Carlos Arturo Levi D’Ancona, Jose Bassani, João Carlos Almeida Division of Urology and Bioengineering, University of.
1 GreenLight XPS™ Laser Therapy System The GOLIATH Study.
Assessment and management of male lower urinary tract symptoms (LUTS)
International Neurourology Journal 2014;18:
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 17, Issue 8, Pages (December 2014)
Volume 72, Issue 1, Pages (January 2017)
International Neurourology Journal 2016;20:
International Neurourology Journal 2015;19:
1Bristol Urological Institute 2Astellas Pharma Europe B.V.
Algorithm for management of symptomatic benign prostatic hyperplasia (BPH). AUASI, American Urological Association symptom index; DRE, digital rectal examination;
Assessment and management of male lower urinary tract symptoms (LUTS)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Rowland Illing  European Urology Supplements 
Volume 55, Issue 2, Pages (February 2009)
Volume 63, Issue 1, Pages (January 2013)
Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)  Raymond C. Rosen, Francois Giuliano, Culley.
Evaluation and Medical Management of Benign Prostatic Hyperplasia
Volume 52, Issue 3, Pages (September 2007)
Rowland Illing  European Urology Supplements 
Volume 60, Issue 1, Pages (July 2011)
Volume 58, Issue 3, Pages (September 2010)
Volume 60, Issue 4, Pages (October 2011)
Volume 61, Issue 3, Pages (March 2012)
Volume 65, Issue 5, Pages (May 2014)
Classification of Male Lower Urinary Tract Symptoms Using Mathematical Modelling and a Regression Tree Algorithm of Noninvasive Near-Infrared Spectroscopy.
P8-2 Rezum water vapour thermal therapy for benign prostatic hyperplasia: early results from the United Kingdom Max Johnston1, Tina Gehring1, James Montgomery1,
Volume 54, Issue 2, Pages (August 2008)
International Neurourology Journal 2015;19:
Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.
Volume 54, Issue 6, Pages (December 2008)
Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.
When to Treat the Prostate, the Bladder, or Both?
A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.
A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.
Volume 53, Issue 6, Pages (June 2008)
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.
Flow diagram of sample selection and reduction of subject numbers by application of exclusion criteria. ‡Data from Medical Record; ‡‡Records missing gender.
Prevalence of air flow obstruction (age-adjusted) by (A) lower limit of normal of forced expiratory ratio versus self-reported doctor diagnosis and (B)
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Primary outcome and patient reported secondary outcomes in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving.
Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery†  L. Tritapepe, V. De Santis, D. Vitale, F. Guarracino,
Kaplan-Meier survival curve for all catheterisations.
Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.
Factors associated with preparedness competency of public health inspectors from the qualitative analysis, which are grouped into three levels according.
Longer testing interval may impact the outcome of a prostate biopsy following the index PSA test due to longer time for a potential tumour to grow from.
Percentage change from baseline in homeostatic model assessment (HOMA) score, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF),
Eye position of positional nystagmus in the right-ear-down and left-ear-down head positions in patients with horizontal canal type of benign paroxysmal.
Relationship between the response to bronchodilator and the pre-bronchodilator FEV1 at visit 2. Relationship between the response to bronchodilator and.
Odds ratio (95% confidence intervals) of reporting respiratory symptoms in patients with treated hypothyroidism or inflammatory bowel disease (IBD) compared.
 Study protocol.  Study protocol. (A) Patients were randomly allocated to placebo or amitriptyline treatment for four weeks. At the end of the month there.
Representativeness of linked cancer registry and dispensed prescription data as compared with cancer registry data alone, by key patient and tumour characteristics.
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Standardised patient wearing the obesity simulation suit used in the present study to represent a patient with type 2 diabetes and grade 2 obesity. The.
Presentation transcript:

Functional secondary outcome parameters in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving prostatic artery embolisation (PAE) or transurethral resection of the prostate (TURP). Functional secondary outcome parameters in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving prostatic artery embolisation (PAE) or transurethral resection of the prostate (TURP). Parameters include (A) maximum urinary flow rate, (B) postvoid residual urine, (C) concentrations of prostate specific antigen (PSA), (D) Prostate volume reduction as assessed by magnetic resonance imaging, (E) desobstruction as measured by detrusor pressure at maximum flow rate (PdetQmax), and (F) urodynamic obstruction as measured by International Continence Society (ICS) classification. I bars=95% confidence intervals; dots=means calculated from the complete dataset at each visit. P values are reported for differences of change from baseline between both treatments. Preop=before the operation (that is, baseline); postop=after the operation. Occasional missing values for secondary outcomes may cause the mean change from baseline to a follow-up visit in (parts A-E) to differ slightly from the difference between mean values at individual time points reported in the text Dominik Abt et al. BMJ 2018;361:bmj.k2338 ©2018 by British Medical Journal Publishing Group